Fecal Microbiota Transplantation Is Safe and Effective in Patients With Clostridioides difficile Infection and Cirrhosis

dc.contributor.authorCheng, Yao-Wen
dc.contributor.authorAlhaffar, Dana
dc.contributor.authorSaha, Srishti
dc.contributor.authorKhanna, Sahil
dc.contributor.authorBohm, Matthew
dc.contributor.authorPhelps, Emmalee
dc.contributor.authorGhabril, Marwan
dc.contributor.authorOrman, Eric
dc.contributor.authorSashidhar, Sagi
dc.contributor.authorRogers, Nicholas
dc.contributor.authorXu, Huiping
dc.contributor.authorKhoruts, Alexander
dc.contributor.authorVaughn, Byron
dc.contributor.authorKao, Dina
dc.contributor.authorWong, Karen
dc.contributor.authorCammarota, Giovanni
dc.contributor.authorIaniro, Gianluca
dc.contributor.authorDhere, Tanvi
dc.contributor.authorKraft, Colleen S.
dc.contributor.authorMehta, Nirja
dc.contributor.authorWoodworth, Michael H.
dc.contributor.authorAllegretti, Jessica R.
dc.contributor.authorNativ, Lotem
dc.contributor.authorMarcus, Jenna
dc.contributor.authorEl-Nachef, Najwa
dc.contributor.authorFischer, Monika
dc.contributor.departmentMedicine, School of Medicineen_US
dc.date.accessioned2020-08-28T21:28:45Z
dc.date.available2020-08-28T21:28:45Z
dc.date.issued2020
dc.description.abstractBackground & Aims Clostridioides difficile infection (CDI) harms a large proportion of patients with cirrhosis. Fecal microbiota transplantation (FMT) is recommended for recurrent CDI, but its effects in patients with cirrhosis have not been established. We performed a multicenter observational study to evaluate the efficacy and safety of FMT for CDI in patients with cirrhosis. Methods We performed a retrospective study of 63 adults with cirrhosis (median model for end-stage liver disease score, 14.5; 24 patients with decompensated cirrhosis) who underwent FMT for CDI from January 2012 through November 2018 at 8 academic centers in the United States, Canada, and Italy. We collected data on patient demographics and characteristics of cirrhosis, CDI, and FMT from medical records and compared differences among patients with different severities of cirrhosis, and FMT successes vs failures at the 8-week follow-up evaluation. We also obtained data on adverse events (AEs) and severe AEs within 12 weeks of FMT. Results Patients underwent FMT for recurrent CDI (55 of 63; 87.3%), severe CDI (6 of 63; 9.5%), or fulminant CDI (2 of 63; 3.2%) primarily via colonoscopy (59 of 63; 93.7%) as outpatients (47 of 63; 76.8%). FMT success was achieved for 54 patients (85.7%). Among FMT failures, a higher proportion used non-CDI antibiotics at the time of FMT (44.4% vs 5.6%; P < .001), had Child–Pugh scores of B or C (100% vs 37.7%; P < .001), used probiotics (77.8% vs 24.1%; P = .003), had pseudomembranes (22.2% vs 0; P = .018), and underwent FMT as inpatients (45.5% vs 19%; P = .039), compared with FMT successes. In multivariable analysis, use of non-CDI antibiotics at the time of FMT (odds ratio, 17.43; 95% CI, 2.00–152.03; P = .01) and use of probiotics (odds ratio, 11.9; 95% CI, 1.81–78.3; P = .01) were associated with a greater risk of FMT failure. FMT-related AEs occurred in 33.3% of patients (21 of 63)—most were self-limited abdominal cramps or diarrhea. There were only 5 severe AEs that possibly were related to FMT; none involved infection or death. Conclusions In a retrospective study, we found FMT to be safe and effective for the treatment of CDI in patients with cirrhosis.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationCheng, Y.-W., Alhaffar, D., Saha, S., Khanna, S., Bohm, M., Phelps, E., Ghabril, M., Orman, E., Sashidhar, S., Rogers, N., Xu, H., Khoruts, A., Vaughn, B., Kao, D., Wong, K., Cammarota, G., Ianiro, G., Dhere, T., Kraft, C. S., … Fischer, M. (2020). Fecal Microbiota Transplantation is Safe and Effective in Patients with Clostridioides difficile Infection and Cirrhosis. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2020.06.051en_US
dc.identifier.urihttps://hdl.handle.net/1805/23748
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.isversionof10.1016/j.cgh.2020.06.051en_US
dc.relation.journalClinical Gastroenterology and Hepatologyen_US
dc.rightsPublisher Policyen_US
dc.sourceAuthoren_US
dc.subjectintestinal microbiotaen_US
dc.subjectinfectious diarrheaen_US
dc.subjectMELDen_US
dc.titleFecal Microbiota Transplantation Is Safe and Effective in Patients With Clostridioides difficile Infection and Cirrhosisen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Cheng_2020_fecal.pdf
Size:
196.13 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: